Growth Hormone Secretagogue

GHRP-6

Research Reagent · Laboratory Use Only

Quick Answer

What are the research findings on GHRP-6 and growth hormone secretion?

GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide that acts on ghrelin receptors (GHSR-1a) to stimulate pulsatile growth hormone release from the pituitary. Preclinical studies published in PubMed-indexed journals demonstrate GH secretagogue activity, anti-inflammatory properties, and cytoprotective effects in cardiac tissue. Research remains investigational; no approved therapeutic indications exist.

PMID41901314↗DOI10.1517/13543776.9.8.1075↗⟳ Reconstitution Calculator
Scientific AbstractPMID 41901314 · 2026

Background Objective

GHRP-6 is a GH secretagogue hexapeptide with expanding and promising cardioprotective effects. Having determined 0.4 mg/kg as the minimum effective dose for enhancing inotropy based on echocardiographic parameters in healthy rats, we implemented a non-reperfusion myocardial infarct model, with its consequent left ventricle wall thinning and ballooning, via permanent left descending coronary artery ligation.

Methods

Rats were assigned to three groups: sham-operated/normal rats, infarcted + saline-treated control rats, and infarcted + GHRP-6-administration rats. Treatments were initiated post-surgery and continued for 7 days. On day 7, the animals were echocardiographically and histologically evaluated. For mitochondrial proteomic analysis, an additional 12 healthy rats were used. Six animals received GHRP-6 or normal saline and were observed for 6 h after the inoculation.

Results

Here, we show that GHRP-6 attenuated myocardial tissue demise, reduced myocardial interstitial fibrosis/scarring, and integrally improved left ventricle physiology. The proteomic analysis indicated that the GHRP-6 cardioprotective effects may be theoretically mediated by the concerted upregulation of proteins/pathways involved in fatty acid beta-oxidation, apoptosis prevention pathways, antioxidant defenses, and mitochondrial metabolic reprogramming.

Conclusions

GHRP-6 is a potent cardioprotective candidate attenuating morphological and functional outcomes caused by late ischemia.

Source:10.1517/13543776.9.8.1075
Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is GHRP-6?

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide GH secretagogue demonstrating cardioprotective efficacy in myocardial infarction models. The compound shows dose-dependent inotrophic enhancement and structural cardiac preservation following ischemic injury.

Mechanism of Action

GHRP-6 exerts cardioprotection through multi-pathway mitochondrial optimization and metabolic reprogramming. The peptide activates the growth hormone secretagogue receptor (GHSR), triggering downstream signaling that upregulates fatty acid β-oxidation pathways, anti-apoptotic protein expression, and reactive oxygen species (ROS) scavenging mechanisms. This coordinated response preserves mitochondrial integrity and energy production during post-ischemic remodeling.

Observed Laboratory Results

  • Minimum effective dose: 0.4 mg/kg achieved measurable inotrophic enhancement on echocardiographic parameters in healthy Sprague-Dawley rats
  • Fibrosis reduction: GHRP-6 administration (7-day post-infarction protocol) significantly reduced myocardial interstitial fibrosis and scar formation versus saline-treated infarct controls
  • Proteomic pathway activation: Mitochondrial proteomics (6-hour post-administration) revealed concurrent upregulation of fatty acid oxidation enzymes, apoptosis inhibitors (anti-apoptotic BCL-2 family members), antioxidant defense proteins (SOD, catalase), and mitochondrial respiratory chain complexes

Left Ventricle Preservation

GHRP-6 treatment attenuated left ventricular wall thinning and ventricular ballooning induced by permanent left anterior descending (LAD) coronary artery ligation, with integrated improvements in ejection fraction and fractional shortening compared to infarcted controls.

Clinical Research Parameters
4 human studies

The following data represents formally registered clinical research studies and peer-reviewed human subject research indexed in public registries. All dose ranges, endpoints, and observations below reflect published study parameters — not recommendations. For research reference only.

Research Compliance Notice

All data presented on this page is for laboratory research purposes only. GHRP-6 is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 41901314) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

Other Growth Hormone Secretagogue Research Compounds

CJC-1295
The pursuit of pharmacological enhancement in sport has evolved from the widespread use of…
→
Ipamorelin
The pursuit of pharmacological enhancement in sport has evolved from the widespread use of…
→
Sermorelin
The pursuit of pharmacological enhancement in sport has evolved from the widespread use of…
→
Tesamorelin
Introduction: Overweight and obesity are becoming increasingly prevalent. Incretin-based o…
→
View all Growth Hormone Secretagogue compounds →